Cargando…

Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application

BACKGROUND: Orthopaedic diseases are one of the major targets for regenerative medicine. In this context, Wharton’s jelly (WJ) is an alternative source to bone marrow (BM) for allogeneic transplantation since its isolation does not require an invasive procedure for cell collection and does not raise...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabrera-Pérez, Raquel, Monguió-Tortajada, Marta, Gámez-Valero, Ana, Rojas-Márquez, Raquel, Borràs, Francesc Enric, Roura, Santiago, Vives, Joaquim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883559/
https://www.ncbi.nlm.nih.gov/pubmed/31779673
http://dx.doi.org/10.1186/s13287-019-1450-3
_version_ 1783474400526336000
author Cabrera-Pérez, Raquel
Monguió-Tortajada, Marta
Gámez-Valero, Ana
Rojas-Márquez, Raquel
Borràs, Francesc Enric
Roura, Santiago
Vives, Joaquim
author_facet Cabrera-Pérez, Raquel
Monguió-Tortajada, Marta
Gámez-Valero, Ana
Rojas-Márquez, Raquel
Borràs, Francesc Enric
Roura, Santiago
Vives, Joaquim
author_sort Cabrera-Pérez, Raquel
collection PubMed
description BACKGROUND: Orthopaedic diseases are one of the major targets for regenerative medicine. In this context, Wharton’s jelly (WJ) is an alternative source to bone marrow (BM) for allogeneic transplantation since its isolation does not require an invasive procedure for cell collection and does not raise major ethical concerns. However, the osteogenic capacity of human WJ-derived multipotent mesenchymal stromal cells (MSC) remains unclear. METHODS: Here, we compared the baseline osteogenic potential of MSC from WJ and BM cell sources by cytological staining, quantitative real-time PCR and proteomic analysis, and assessed chemical and biological strategies for priming undifferentiated WJ-MSC. Concretely, different inhibitors/activators of the TGFβ1-BMP2 signalling pathway as well as the secretome of differentiating BM-MSC were tested. RESULTS: Cytochemical staining as well as gene expression and proteomic analysis revealed that osteogenic commitment was poor in WJ-MSC. However, stimulation of the BMP2 pathway with BMP2 plus tanshinone IIA and the addition of extracellular vesicles or protein-enriched preparations from differentiating BM-MSC enhanced WJ-MSC osteogenesis. Furthermore, greater outcome was obtained with the use of conditioned media from differentiating BM-MSC. CONCLUSIONS: Altogether, our results point to the use of master banks of WJ-MSC as a valuable alternative to BM-MSC for orthopaedic conditions.
format Online
Article
Text
id pubmed-6883559
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68835592019-12-03 Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application Cabrera-Pérez, Raquel Monguió-Tortajada, Marta Gámez-Valero, Ana Rojas-Márquez, Raquel Borràs, Francesc Enric Roura, Santiago Vives, Joaquim Stem Cell Res Ther Research BACKGROUND: Orthopaedic diseases are one of the major targets for regenerative medicine. In this context, Wharton’s jelly (WJ) is an alternative source to bone marrow (BM) for allogeneic transplantation since its isolation does not require an invasive procedure for cell collection and does not raise major ethical concerns. However, the osteogenic capacity of human WJ-derived multipotent mesenchymal stromal cells (MSC) remains unclear. METHODS: Here, we compared the baseline osteogenic potential of MSC from WJ and BM cell sources by cytological staining, quantitative real-time PCR and proteomic analysis, and assessed chemical and biological strategies for priming undifferentiated WJ-MSC. Concretely, different inhibitors/activators of the TGFβ1-BMP2 signalling pathway as well as the secretome of differentiating BM-MSC were tested. RESULTS: Cytochemical staining as well as gene expression and proteomic analysis revealed that osteogenic commitment was poor in WJ-MSC. However, stimulation of the BMP2 pathway with BMP2 plus tanshinone IIA and the addition of extracellular vesicles or protein-enriched preparations from differentiating BM-MSC enhanced WJ-MSC osteogenesis. Furthermore, greater outcome was obtained with the use of conditioned media from differentiating BM-MSC. CONCLUSIONS: Altogether, our results point to the use of master banks of WJ-MSC as a valuable alternative to BM-MSC for orthopaedic conditions. BioMed Central 2019-11-28 /pmc/articles/PMC6883559/ /pubmed/31779673 http://dx.doi.org/10.1186/s13287-019-1450-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Cabrera-Pérez, Raquel
Monguió-Tortajada, Marta
Gámez-Valero, Ana
Rojas-Márquez, Raquel
Borràs, Francesc Enric
Roura, Santiago
Vives, Joaquim
Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application
title Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application
title_full Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application
title_fullStr Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application
title_full_unstemmed Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application
title_short Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application
title_sort osteogenic commitment of wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883559/
https://www.ncbi.nlm.nih.gov/pubmed/31779673
http://dx.doi.org/10.1186/s13287-019-1450-3
work_keys_str_mv AT cabreraperezraquel osteogeniccommitmentofwhartonsjellymesenchymalstromalcellsmechanismsandimplicationsforbioprocessdevelopmentandclinicalapplication
AT monguiotortajadamarta osteogeniccommitmentofwhartonsjellymesenchymalstromalcellsmechanismsandimplicationsforbioprocessdevelopmentandclinicalapplication
AT gamezvaleroana osteogeniccommitmentofwhartonsjellymesenchymalstromalcellsmechanismsandimplicationsforbioprocessdevelopmentandclinicalapplication
AT rojasmarquezraquel osteogeniccommitmentofwhartonsjellymesenchymalstromalcellsmechanismsandimplicationsforbioprocessdevelopmentandclinicalapplication
AT borrasfrancescenric osteogeniccommitmentofwhartonsjellymesenchymalstromalcellsmechanismsandimplicationsforbioprocessdevelopmentandclinicalapplication
AT rourasantiago osteogeniccommitmentofwhartonsjellymesenchymalstromalcellsmechanismsandimplicationsforbioprocessdevelopmentandclinicalapplication
AT vivesjoaquim osteogeniccommitmentofwhartonsjellymesenchymalstromalcellsmechanismsandimplicationsforbioprocessdevelopmentandclinicalapplication